Intracellular transduction and potential of Tat PTD and its analogs: From basic drug delivery mechanism to application

Expert Opinion on Drug Delivery

Volumn 9, Issue 4, 2012, Pages 457-472

  Zhang, Xinke ^a   Zhang, Xue ^b   Wang, Fengshan ^a  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Mechanism; Systemic delivery; Targeted systems; Tat PTD; Topical delivery

Indexed keywords

CLATHRIN; CYCLOSPORIN A; DELCASERTIB; GAG PROTEIN; HEAT SHOCK PROTEIN; LIPID; MATRIX METALLOPROTEINASE; NEUROGLOBIN; PEPTIDE DERIVATIVE; PHOSPHATIDYLINOSITIDE; PLOYARGININE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ACIDITY; BLOOD BRAIN BARRIER; BRAIN DISEASE; CAVEOLA; CELL MEMBRANE; CELL MIGRATION; CELL SURFACE; DRUG ABSORPTION; DRUG BINDING; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ENDOSOME; EYE DISEASE; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYDROGEN BOND; HYPOXIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NEOPLASM; NONHUMAN; PH; PINOCYTOSIS; REVIEW; SIGNAL TRANSDUCTION; SKIN DISEASE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STATIC ELECTRICITY;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, OPHTHALMIC; ADMINISTRATION, TOPICAL; ANIMALS; CAVEOLAE; CELL MEMBRANE; CLATHRIN; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; GENE PRODUCTS, TAT; HIV-1; HUMANS; MATRIX METALLOPROTEINASES; MYOCARDIAL ISCHEMIA; NEOPLASMS; PEPTIDES; PINOCYTOSIS; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; SKIN DISEASES; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION; TRANSDUCTION, GENETIC;

EID: 84863380035     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.663351     Document Type: Review

References (100)

1. Noguchi H, Matsushita M, Kobayashi N, et al. Recent advances in protein transduction technology. Cell Transplant 2010;19(6-7):649-54
2. Sawant R, Torchilin V. Intracellular transduction using cell-penetrating peptides. Mol Biosyst 2010;6(4):628-40
3. Joliot A, Prochiantz A. Transduction peptides: From technology to physiology. Nat Cell Biol 2004;6(3):189-96
4. Trehin R, Merkle HP. Chances and pitfalls of cell penetrating peptides for cellular drug delivery. Eur J Pharm Biopharm 2004;58(2):209-23
5. Ziegler A. Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and glycosaminoglycans. Adv Drug Deliv Rev 2008;160(4-5):580-97 A review about concrete binding mechanism of different CPPs.
6. Bolhassani A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta 2011;1816(2):232-46
7. Divita G, Heitz F, Morris MC. Twenty years of cell-penetrating peptides: From molecular mechanisms to therapeutics. Br J Pharmacol 2009;157(2):195-206
8. Brasseur R, Divita G. Happy birthday cell penetrating peptides: Already 20 years. Bba Biomembranes 2010;1798(12):2177-81
9. Snyder EL, Dowdy SF. Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids invivo. Expert OpinDrug Deliv 2005; 2(1):43-51 This is a nice review on evidence that PTDs are used both to deliver active molecules to pathological tissue in vivo and to treat models of disease such as cancer, ischaemia and inflammation.
10. Brooks NA, Pouniotis DS, Tang CK, et al. Cell-penetrating peptides: Application in vaccine delivery. Bba Rev Cancer 2010;1805(1):25-34
11. Arthanari Y, Pluen A, Rajendran R, et al. Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting bcr-Abl fusion gene in Chronic Myeloid Leukemia cells. J Control Release 2010;145(3):272-80
12. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988;55(6):1189-93
13. Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 1994;91(2):664-8
14. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997;Jun20272(25):16010-17
15. Schwarze SR, Ho A, Vocero-Akbani A, et al. In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 1999;285(5433):1569-72 In vivo systemic delivery of enzymatically active Tat PTD-fusion protein.
16. Brooks H, Lebleu B, Vives E. Tat peptide-mediated cellular delivery: Back to basics. Adv Drug Deliv Rev 2005;57(4):559-77 This article reviewed different influential factor on mechanism of Tat PTD.
17. Nam HY, Kim J, Kim S, et al. Cell penetrating peptide conjugated bioreducible polymer for siRNA delivery. Biomaterials 2011;32(22):5213-22
18. Howl J, Nicholl ID, Jones S. The many futures for cell-penetrating peptides: How soon is now? Biochem Soc Trans 2007;35:767-9
19. Rapoport M, Lorberboum-Galski H. TAT-based drug delivery system - new directions in protein delivery for new hopes? Expert Opin Drug Deliv 2009;6(5):453-63
20. Vives E. Present and future of cell-penetrating peptide mediated delivery systems: "Is the Trojan horse too wild to go only to Troy?". J Control Release 2005;109(1-3):77-85 This review summarized the problems of CPPs for drug delivery in vivo and described some strategies to overcome these limitations.
21. Kawamoto S, Takasu M, Miyakawa T, et al. Inverted micelle formation of cell-penetrating peptide studied by coarse-grained simulation: Importance of attractive force between cell-penetrating peptides and lipid head group. J Chem Phys 2011;134(9):095103
22. Gillmeister MP, Betenbaugh MJ, Fishman PS. Cellular trafficking and photochemical internalization of cell penetrating peptide linked cargo proteins: A dual fluorescent labeling study. Bioconjugate Chem 2011;22(4):556-66
23. Esbjorner EK, Amand HL, Bostrom CL, et al. Binding of cell-penetrating penetratin peptides to plasma membrane vesicles correlates directly with cellular uptake. Bba Biomembranes 2011;1808(7):1860-7
24. Raagel H, Saalik P, Pooga M. Peptide-mediated protein delivery-Which pathways are penetrable? Bba Biomembranes 2010;1798(12):2240-8
25. Hassane FS, Saleh AF, Abes R, et al. Cell penetrating peptides: Overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci 2010;67(5):715-26
26. Vives E, Schmidt J, Pelegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 2008;1786(2):126-38
27. Rullo A, Qian J, Nitz M. Peptide-glycosaminoglycan cluster formation involving cell penetrating peptides. Biopolymers 2011;95(10):722-31
28. Butko P, Tiriveedhi V. A fluorescence spectroscopy study on the interactions of the TAT-PTD peptide with model lipid membranes. Biochemistry Us 2007;46(12):3888-95
29. Ziegler A, Blatter XL, Seelig A, et al. Protein transduction domains of HIV-1 and SIV TAT interact with charged lipid vesicles. Binding mechanism and thermodynamic analysis. Biochemistry 2003;42(30):9185-94
30. Esko JD, Bishop JR, Schuksz M. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007;446(7139):1030-7
31. Letoha T, Keller-Pinter A, Kusz E, et al. Cell-penetrating peptide exploited syndecans. Bba Biomembranes 2010;1798(12):2258-65
32. Richard JP, Melikov K, Brooks H, et al. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem 2005;280(15):15300-6
33. Tyagi M, Rusnati M, Presta M, et al. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 2001;276(5):3254-61
34. Kichler A, Mason AJ, Bechinger B. Cationic amphipathic histidine-rich peptides for gene delivery. Bba Biomembranes 2006;1758(3):301-7
35. Piwnica-Worms D, Violini S, Sharma V, et al. Evidence for a plasma membrane-mediated permeability barrier to tat basic domain in well-differentiated epithelial cells: Lack of correlation with heparan sulfates. Biochemistry 2002;41(42):12652-61
36. de Mendoza J, Blondeau P, Segura M, et al. Molecular recognition of oxoanions based on guanidinium receptors. Chem Soc Rev 2007;36(2):198-210
37. Su YC, Waring AJ, Ruchala P, et al. Membrane-Bound Dynamic structure of an arginine-rich cell-penetrating peptide, the protein transduction domain of HIV TAT, from Solid-State NMR. Biochemistry 2010;49(29):6009-20
38. Ziegler A, Seelig J. Binding and clustering of glycosaminoglycans: A common property of mono- And multivalent cell-penetrating compounds. Biophys J 2008;94(6):2142-9
39. Futaki S, Nakase I, Takeuchi T, et al. Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides. Adv Drug Deliv Rev 2008;60(4-5):598-607
40. Futaki S, Nakase I, Tadokoro A, et al. Interaction of arginine-rich peptides with membrane-Associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochemistry Us 2007;46(2):492-501
41. Bernfield M, Gotte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999;68:729-77
42. Ter-Avetisyan G, Tunnemann G, Nowak D, et al. Cell entry of arginine-rich peptides is independent of endocytosis. J Biol Chem 2009;284(6):3370-8
43. Eiriksdottir E, Mager I, Lehto T, et al. Cellular internalization kinetics of (Luciferin-)cell-penetrating peptide conjugates. Bioconjugate Chem 2010;21(9):1662-72
44. Liu BR, Huang YW, Chiang HJ, et al. Cell-Penetrating peptide- functionalized quantum dots for intracellular delivery. J Nanosci Nanotechnol 2010;10(12):7897-905
45. Brock R, Duchardt F, Fotin-Mleczek M, et al. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 2007;8(7):848-66
46. Futaki S, Nakase I, Taclokoro A, et al. Arginine-rich peptides and their internalization mechanisms. Biochem Soc Trans 2007;35:784-7
47. Zhang XP, Jin YJ, Pllummer MR, et al. Endocytosis and membrane potential are required for hela cell uptake of RI-CKTat9, a retro-inverso tat cell penetrating peptide. Mol Pharm 2009;6(3):836-48 This study focused on the effects of endocytosis and membrane potential in the cellular entry of Tat PTD.
48. Wender PA, Rothbard JB, Jessop TC. Adaptive translocation: The role of hydrogen bonding and membrane potential in the uptake of guanidinium-rich transporters into cells. Adv Drug Deliv Rev 2005;57(4):495-504
49. Ferrari A, Pellegrini V, Arcangeli C, et al. Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. Mol Ther 2003;8(2):284-94
50. Raub TJ, Roberts RM. Cell surface glycoproteins of CHO cells. II. Surface distribution and pathway of internalization. Exp Cell Res 1986;165(1):92-106
51. Huang M, Ma Z, Khor E, et al. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharm Res 2002;19(10):1488-94
52. Bruyninckx WJ, Comerford KM, Lawrence DW, et al. Phosphoinositide 3-kinase modulation of beta(3)-integrin represents an endogenous "braking" mechanism during neutrophil transmatrix migration. Blood 2001;97(10):3251-8
53. Jones SW, Christison R, Bundell K, et al. Characterisation of cell-penetrating peptide-mediated peptide delivery. Br J Pharmacol 2005;145(8):1093-102
54. Giacca M, Fittipaldi A. Transcellular protein transduction using the Tat protein of HIV-1. Adv Drug Deliv Rev 2005;57(4):597-608
55. Nakase I, Niwa M, Takeuchi T, et al. Cellular uptake of arginine-rich peptides: Roles for macropinocytosis and actin rearrangement. Mol Ther 2004;10(6):1011-22
56. Jones AT. Macropinocytosis: Searching for an endocytic identity and role in the uptake of cell penetrating peptides. J Cell Mol Med 2007;11(4):670-84
57. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004;10(3):310-15
58. Yang ST, Zaitseva E, Chernomordik LV, et al. Cell-Penetrating peptide induces leaky fusion of liposomes containing late endosome-specific anionic lipid. Biophys J 2010;99(8):2525-33
59. Howl J, Jones S. Transport molecules using reverse sequence HIV-Tat polypeptides: Not just any old Tat? (WO200808225). Expert Opin Ther Patent 2009;19(9):1329-33
60. Rothbard JB, Garlington S, Lin Q, et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 2000;6(11):1253-7
61. Schorderet DF, Manzi VD, Canola K, et al. D-TAT transporter as an ocular peptide delivery system. Clin Exp Ophthalmol 2005; 33(6):628-35
62. Dietz GPH, Kilic E, Bahr M. Inhibition of neuronal apoptosis in vitro and in vivo using TAT-Mediated protein transduction. Mol Cell Neurosci 2002;21(1):29-37 A study to illustrate the feasibility of Tat PTD to cross the eye barriers.
63. Wang Y, Lin H, Lin S, et al. Cell-penetrating peptide TAT-mediated delivery of acidic FGF to retina and protection against ischemia-reperfusion injury in rats. J Cell Mol Med 2010;14(7):1998-2005 A study to evaluate the efficacy of Tat PTD to deliver acidic FGF (aFGF) to retina in rats.
64. Miyaji Y, Walter S, Chen L, et al. Distribution of KAI-9803, a novel {delta} PKC inhibitor, after intravenous administration to rats. Drug Metab Dispos 2011;39(10):1946-53
65. Doeppner TR, El Aanbouri M, Dietz GP, et al. Transplantation of TATBcl- xL-transduced neural precursor cells: Long-term neuroprotection after stroke. Neurobiol Dis 2010;40(1):265-76
66. Yonezawa T, Kurata R, Kimura M, et al. PKC delta and epsilon in drug targeting and therapeutics. Recent Pat DNA Gene Seq 2009;3(2):96-101
67. Bates E, Bode C, Costa M, et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 2008;117(7):886-96
68. Metzler B, Xu Q, Mayr M. Letter by Metzler et al regarding article, "Intracoronary KAI-9803 as an adjunct to primary coronary intervention for acute ST-segment elevation myocardial infarction". Circulation 2008;118(4):e80
69. Hirt L, Badaut J, Thevenet J, et al. D-JNKI1, a cell-penetrating c-Jun-Nterminal kinase inhibitor, protects against cell death in severe cerebral ischemia. Stroke 2004;35(7):1738-43
70. Repici M, Borsello T. JNK pathway as therapeutic target to prevent degeneration in the central nervous system. Hypoxia and Exercise 2006;588:145-55
71. Ohta Y, Kamiya T, Nagai M, et al. Therapeutic benefits of intrathecal protein therapy in a mouse model of amyotrophic lateral sclerosis. J Neurosci Res 2008;86(13):3028-37
72. Boisguerin P, Redt-Clouet C, Franck-Miclo A, et al. Systemic delivery of BH4 anti-Apoptotic peptide using CPPs prevents cardiac ischemia-reperfusion injuries in vivo. J Control Release 2011;156(2):146-53
73. Dietz GP. Protection by neuroglobin and cell-penetrating peptide-mediated delivery in vivo: A decade of research Comment on Cai et al.: TAT-mediated delivery of neuroglobin protects against focal cerebral ischemia in mice. Exp Neurol 2011;227(1):224-31
74. Cai B, Lin Y, Xue XH, et al. TAT-mediated delivery of neuroglobin protects against focal cerebral ischemia in mice. Exp Neurol 2011;227(1):224-31
75. Doeppner TR, Dietz GP, Weise J, et al. Protection of hippocampal neurogenesis by TAT-Bcl-x(L) after cerebral ischemia in mice. Exp Neurol 2010;223(2):548-56
76. Dietz GPH. Cell-Penetrating peptide technology to deliver chaperones and associated factors in diseases and basic research. Curr Pharm Biotechnol 2010;11(2):167-74
77. Doeppner TR, Nagel F, Dietz GP, et al. TAT-Hsp70-mediated neuroprotection and increased survival of neuronal precursor cells after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2009;29(6):1187-96
78. Nagel F, Falkenburger BH, Tonges L, et al. Tat-Hsp70 protects dopaminergic neurons in midbrain cultures and in the substantia nigra in models of Parkinson's disease. J Neurochem 2008;105(3):853-64
79. Simon MJ, Kang WH, Gao S, et al. Increased delivery of TAT across an endothelial monolayer following ischemic injury. Neurosci Lett 2010;486(1):1-4
80. Simon MJ, Kang WH, Gao S, et al. TAT is not capable of transcellular delivery across an intact endothelial monolayer in vitro. Ann Biomed Eng 2011;39(1):394-401 A recent study to prove Tat can not cross an intacr endothelial monolayer.
81. Harada H, Kizaka-Kondoh S, Hiraoka M. Antitumor protein therapy; application of the protein transduction domain to the development of a protein drug for cancer treatment. Breast Cancer 2006;13(1):16-26 This review article focused on the application of PTD to develop antitumor macromolecules and introduce several representative strategies to discriminate between tumor and normal tissue.
82. Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 2005;57(4):579-96
83. Bitler BG, Schroeder JA. Anti-Cancer therapies that utilize cell penetrating peptides. Recent Pat AntiCancer 2010;5(2):99-108
84. Tsien RY, Jiang T, Olson ES, et al. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 2004;101(51):17867-72
85. Kwon YM, Li Y, Naik S, et al. The ATTEMPTS delivery systems for macromolecular drugs. Expert Opin Drug Deliv 2008;5(11):1255-66 A review on the The "ATTEMPTS" delivery systems bulit by Yang's group.
86. Huang YZ, Park YS, Wang JX, et al. ATTEMPTS System: A macromolecular prodrug strategy for cancer drug delivery. Curr Pharm Des 2010;16(21):2369-76
87. Kizaka-Kondoh S, Harada H, Hiraoka M. Antitumor effect of TAT-oxygen-dependent degradationcaspase- 3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res 2002;62(7):2013-18
88. Inoue M, Mukai M, Hamanaka Y, et al. Targeting hypoxic cancer cells with a protein prodrug is effective in experimental malignant ascites. Int J Oncol 2004;25(3):713-20
89. Olson ES, Aguilera TA, Jiang T, et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol (Camb) 2009;1(5-6):382-93
90. Aguilera TA, Olson ES, Timmers MM, et al. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol (Camb) 2009;1(5-6):371-81
91. Naik SS, Liang JF, Park YJ, et al. Application of "ATTEMPTS" for drug delivery. J Control Release 2005;101(1-3):35-45
92. Yang VC, Kwon YM, Li YT, et al. PTD-modified ATTEMPTS system for enhanced asparaginase therapy: A proof-of-concept investigation. J Control Release 2008;130(3):252-8
93. Li YT, Kwon YM, Spangrude GJ, et al. Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy. J Biomed Mater Res A 2009;91(1):209-20
94. Sawant R, Torchilin V. Intracellular delivery of nanoparticles with CPPs. Methods Mol Biol 2011;683:431-51 This review described the method for preparation of "smart" nanocarrier with hidden TATp function.
95. Torchilin VP. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 2008;60(4-5):548-58 This review addressed the development of "smart" stimuli-sensitive nanocarriers.
96. Torchilin VP. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 2008;90(5):604-10
97. Kale AA, Torchilin VP. Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes. J Drug Target 2007;15(7-8):538-45
98. Sethuraman VA, Bae YH. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Control Release 2007;118(2):216-24 This study constructed a novel targeting system based Tat PTD.
99. Sethuraman VA, Lee MC, Bae YH. A biodegradable pH-sensitive micelle system for targeting acidic solid tumors. Pharm Res 2008;25(3):657-66
100. Lee ES, Gao Z, Kim D, et al. Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. J Control Release 2008;129(3):228-36